MOLOGNI LUCA

Zapata Dongo, R., Fontana, D., Mologni, L., Faya Castillo, J., Infante, V. (2025). Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer. Intervento presentato a: Barcelona BioMed Conferences. AI in Drug Discovery and Biomedicine, Barcelona, Spain. Dettaglio

Zapata Dongo, R., Poterico, J., Fontana, D., Mologni, L., Alvarez-Chacon, C., Rojas-Armas, J., et al. (2025). An in silico evaluation of lorlatinib as a potential therapy for novel amino acid substitutions in the tyrosine kinase domain of the ALK protein associated with cancer. FRONTIERS IN PHARMACOLOGY, 16 [10.3389/fphar.2025.1605314]. Dettaglio

Crippa, V., Cordani, N., Villa, A., Malighetti, F., Villa, M., Sala, L., et al. (2025). Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer. NPJ PRECISION ONCOLOGY, 9(1) [10.1038/s41698-025-01088-0]. Dettaglio

Pattabiraman, N., Lobello, C., Rushmore, D., Mologni, L., Wasik, M., Basappa, J. (2025). A Novel Allosteric Inhibitor Targeting IMPDH at Y233 Overcomes Resistance to Tyrosine Kinase Inhibitors in Lymphoma. CANCERS, 17(20) [10.3390/cancers17203389]. Dettaglio

Crippa, V., Cordani, N., Villa, A., Malighetti, F., Villa, M., Sala, L., et al. (2025). Author Correction: Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer (npj Precision Oncology, (2025), 9, 1, (291), 10.1038/s41698-025-01088-0) [Altro] [10.1038/s41698-025-01114-1]. Dettaglio